1. Home
  2. VTGN vs DKI Comparison

VTGN vs DKI Comparison

Compare VTGN & DKI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo VistaGen Therapeutics Inc.

VTGN

VistaGen Therapeutics Inc.

HOLD

Current Price

$0.24

Market Cap

10.8M

Sector

Health Care

ML Signal

HOLD

DKI

DarkIris Inc. Class A Ordinary Shares

HOLD

Current Price

$2.80

Market Cap

10.0M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
VTGN
DKI
Founded
1998
2018
Country
United States
Hong Kong
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.8M
10.0M
IPO Year
2014
2025

Fundamental Metrics

Financial Performance
Metric
VTGN
DKI
Price
$0.24
$2.80
Analyst Decision
Hold
Analyst Count
3
0
Target Price
$0.90
N/A
AVG Volume (30 Days)
716.8K
94.1K
Earning Date
06-16-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$124.49
N/A
Revenue Next Year
$353.99
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.20
$0.28
52 Week High
$5.14
$11.80

Technical Indicators

Market Signals
Indicator
VTGN
DKI
Relative Strength Index (RSI) 41.27 29.68
Support Level $0.23 $0.34
Resistance Level $0.32 $5.20
Average True Range (ATR) 0.02 0.24
MACD 0.00 -0.09
Stochastic Oscillator 31.67 13.71

Price Performance

Historical Comparison
VTGN
DKI

About VTGN VistaGen Therapeutics Inc.

Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.

About DKI DarkIris Inc. Class A Ordinary Shares

Darkiris Inc is a comprehensive technology enterprise engaged in the development, publishing and operating of mobile digital games via various third-party digital storefronts. Its activities encompass including game design, programming and graphics, as well as distribution and operation of mobile games on various platforms. Its core product offerings are Games Development; develop, market and distribute its self-developed mobile games; and Games Publishing and Operation. It publish and operate its self-developed mobile games and mobile games it license from other game developers.

Share on Social Networks: